GSK’s share price has fallen. I’d buy the stock today

GSK’s share price has fallen from near 1,800p to around 1,400p over the last year. Edward Sheldon believes it offers a lot of value at current levels.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) shares have underperformed over the last year. This time last year, GSK’s share price was hovering just below 1,800p. Today however, it’s near 1,400p – more than 20% lower.

At the current share price, I see the shares as a ‘buy’. Here’s a look at why I like the FTSE 100 stock right now.

GSK shares: long-term growth potential

While GlaxoSmithKline’s recent results haven’t been amazing, the long-term growth prospects for the company remain quite attractive, in my view. Glaxo specialises in three areas of the healthcare market – pharmaceuticals, vaccines and consumer healthcare. In today’s world, these areas are all highly relevant.

Pharmaceuticals is GSK’s largest division. Last year, it generated sales of £17.6bn – about 52% of total sales. Here, the company has a broad portfolio of medicines in respiratory, HIV, immuno-inflammation and oncology. It’s also strengthening its R&D pipeline in areas such as immunology and human genetics.

Going forward, demand for pharmaceuticals should continue to grow. The growing global population, rising wealth in the emerging markets and the increasing prevalence of major health conditions will be some key growth drivers.

GSK’s vaccines division also looks to have potential. Vaccines are a crucial component of modern healthcare. Every year, they prevent two to three million deaths globally. In 2019, the global vaccine market was worth just under $50bn. However, experts believe the market could be worth over $100bn by 2027. As the leader in the vaccines space, GSK should benefit.

Finally, the consumer healthcare division shouldn’t be ignored. Here, GSK is also a market leader in pain relief, digestive health and therapeutic oral health. With demand for consumer health products set to rise in the years ahead due to the world’s ageing population, GSK looks well-placed for growth.

Share price upside

Aside from the company’s long-term growth potential, there are other reasons I like GSK shares right now. One is that the company is about to separate its consumer health business. This could add value for shareholders. My colleague Roland Head believes investors are likely to apply a higher valuation to the consumer division once it’s separated from the group.

Another reason I’m bullish here is that there’s been some interesting insider buying here recently. Regulatory filings show that late last year, senior independent director Manvinder Singh Banga – who previously spent 33 years at Unilever – spent approximately £500,000 on GSK shares. Insiders only buy stock for one reason – they expect it to go up.

Strong value

After the recent share price fall, GSK shares now trade at an attractive valuation. City analysts expect the company to generate earnings of 117p per share this year, which means, at the current share price, the stock’s forward-looking P/E ratio is just 12. At that valuation, I think the risk/reward proposition is very attractive. There’s also a dividend yield of 5.8%, which adds weight to the investment case.

Overall, I think there’s a lot to like about GSK shares right now. With the stock trading near 1,400p, I’d buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline and Unilever. The Motley Fool UK has recommended GlaxoSmithKline and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »